Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses

Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza, and respiratory syncytial virus (RSV) are significant global health threats. The need for low-cost, easily synthesized oral drugs for rapid deployment during outbreaks is crucial. Broad-spectrum therapeutics, or pan-antivirals,...

Full description

Bibliographic Details
Main Authors: Harry Ridgway, Vasso Apostolopoulos, Graham J. Moore, Laura Kate Gadanec, Anthony Zulli, Jordan Swiderski, Sotirios Tsiodras, Konstantinos Kelaidonis, Christos T. Chasapis, John M. Matsoukas
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Viruses
Subjects:
arginine blockers
bisartans
benzimidazole sartans
coronavirus 2019
influenza
pan-antivirals
Online Access:https://www.mdpi.com/1999-4915/16/11/1776

Internet

https://www.mdpi.com/1999-4915/16/11/1776

Similar Items